



16 July 2021

Creso Pharma launches cannaDOL® through multiple distribution channels to target Swiss sports, health and wellness markets

Highlights:


- Creso Pharma launches innovative cannaDOL® formulations to the Swiss sports market through newly established ecommerce channel, as well as through pharmacies, drug stores and sports & fitness centres
- Creso Pharma finalised the conception and technical evaluation of:
 - cannaDOL® Boost for use before sports activity; and
 - cannaDOL® Recovery for after physical activity to enhance recovery
- Creso Pharma has access to key wholesalers in Switzerland and reaches over 2,100 pharmacies, drugstores and over 400 sports & fitness centers as point of sales
- Further distribution into the sports markets in European countries are being established - Poland and Portugal earmarked for near term expansion

Creso Pharma Limited (ASX: CPH, OTC: COPHF FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise that it has finalised a number of steps to launch its newly developed, innovative cannaDOL® gel products into the sport, health and wellness markets in Switzerland through all established commercial channels and the recently developed Creso Pharma cannaDOL® ecommerce website.

The launch follows considerable research, development and technical evaluation of the cannaDOL® product portfolio. Following this, the Company has developed two new products, including **cannaDOL® Boost**, which is to be used before sport and recreational activity and **cannaDOL® Recovery**, which aids in recovery from sport and other physical activities. Both complementary products use the newly developed hemp CBD tea-based technology. **cannaDOL® Boost** ingredients are based on a unique formula of caffeine, taurine, vitamins and minerals providing an energy boost, whereas **cannaDOL® Recovery** is based on a unique formula containing lemon balm and curcumin in addition to vitamins and minerals.

Creso Pharma will now launch the new products through its established distribution footprint and commercial partners to target the lucrative sporting, recreation and health and fitness markets. The Company is also progressing product introduction across a number of European markets including Poland and Portugal. Ongoing expansion initiatives and go to market strategies are being explored.

Creso Pharma has access to a number of major wholesalers in Switzerland with the Company's reach extending to over 2,100 points of sale including pharmacies, pharmacy networks, drugstores and over 400 sport & fitness centres. Amongst these is the large retail shop Manor, which is a major department store chain with stores across Switzerland. Creso Pharma is currently supplying all major wholesalers in the country such as Galexis, Amedis and Voigt.



cannaDOL® Brand Ambassador
Jenny Dietschweiler
Figure athlete
WM WFF Figure Class



cannaDOL®0.5%, 1%
100 ml gel tubes



cannaDOL® Boost

Management commentary:

Creso Commercial Director Dr. Gian Trepp, said: “The recent development of our ecommerce channel and new products formulations is a very pleasing development and we are proud to substantially strengthen our sport products portfolio with cannaDOL® Boost and Recovery.

“Recent initiatives will assist the Company to expand its leading presence in the Swiss and European sports markets, which provide another high yield and low risk opportunity for the Company. Discussions with additional partners and specialty retailers are ongoing and we anticipate that further growth can be achieved across Europe and more broadly.”

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

**Released through:**

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX: CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.